Beschreibung
The p53 polymorphism on codon 72 appears to modulate the proapoptotic activity of the protein and might have a negative impact on cancer risk and clinical outcome. In this study, the frequency of different p53 genotypes was assessed in a cohort of neuroblastoma patients: patients with the Pro/Pro genotype appear to have a significantly shorter overall survival compared to those with the Arg/Pro or Arg/Arg genotype. This suggests that the Pro/Pro genotype may identify a subgroup of neuroblastoma patients with aggressive disease. To assess the effects of p53 activation after chemotherapy or radiotherapy, derivative cell lines expressing an inducible form of p53 were established. It was found that the frequency of apoptotic cells with Arg/Arg genotype was higher than those with Pro/Pro genotype. Although there are highly effective therapies for patients with low or intermediate risk neuroblastomas, recurrent disease in patients with high risk remains a challenge. Thus, this study may be useful for a more complete genetic characterization of neuroblastomas at diagnosis and for improving risk stratification and, possibly, therapeutic responses in patients.
Autorenporträt
Jenny Vergalli is an Italian scientist with biotechnological background.Her strong attitude to research enabled her to acquire a broad and solid foundation in biomedical sciences. Since her early academic career, she has contributed to several research projects, predominantly concerning human cancer biology.
Herstellerkennzeichnung:
OmniScriptum SRL
Str. Armeneasca 28/1, office 1
2012 Chisinau
MD
E-Mail: info@omniscriptum.com
![Produktbild: Acoustic correlates of [voice]](http://medien.umbreitkatalog.de/bildzentrale/978/383/834/3068.jpg)
